2022
Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue
Wisnewski AV, Cantley L, Luna J, Liu J, Smith RF, Hager K, Redlich CA. Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue. Journal Of Occupational And Environmental Medicine 2022, 64: 788-796. PMID: 36054278, PMCID: PMC9426317, DOI: 10.1097/jom.0000000000002617.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19COVID-19 VaccinesHumansImmunoglobulin GIncidenceNorth AmericaVaccinationVideo GamesConceptsOccupational risk factorsCOVID-19 historyRisk factorsAnti-spike IgG levelsIndividual humoral responsesSerum antiviral antibodiesCOVID-19 vaccinationEnzyme-linked immunosorbent assayCOVID-19 ratesCOVID-19 incidenceSpike IgGVaccine nonrespondersVaccination statusIgG levelsVaccine responsesVaccine typesAntiviral antibodiesHumoral responseCOVID-19 casesVaccine availabilityImmunosorbent assayVaccinationInfectionMonthsParticipants
2021
Human IgG and IgA responses to COVID-19 mRNA vaccines
Wisnewski AV, Luna J, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA vaccines. PLOS ONE 2021, 16: e0249499. PMID: 34133415, PMCID: PMC8208542, DOI: 10.1371/journal.pone.0249499.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccinesAntigen-specific IgGMRNA vaccinesIgG levelsCOVID-19 mRNA vaccinationAntigen-specific IgG levelsInitial vaccine doseAntigen-specific IgASARS-CoV-2More rapid declineSecond vaccineVaccine doseMRNA vaccinationIgA responsesSerum levelsVaccine dosesSpecific IgGNatural immunityViral neutralizationIgAVaccinePeak levelsIgGVaccinationHuman IgG
1995
Induction of protective immunity to schistosomiasis with immunologically cross-reactive Lumbricus molecules
Wisnewski AV, Kresina TF. Induction of protective immunity to schistosomiasis with immunologically cross-reactive Lumbricus molecules. International Journal For Parasitology 1995, 25: 503-510. PMID: 7543459, DOI: 10.1016/0020-7519(94)00132-8.Peer-Reviewed Original ResearchConceptsVaccination of miceCandidate vaccine moleculesS. japonicum infectionS. japonicum paramyosinSchistosomiasis patients' seraMurine immune seraSchistosomiasis patientsProtective immunitySchistosome infectionPatient seraJaponicum infectionImmune serumUninfected individualsAntibody productionAntigen preparationsVaccine moleculesMultiple antigensRodent seraParasite moleculesMurine antibodyCross-reactive moleculesS. japonicumSerumAntigenSchistosoma japonicum